TRADES
Latest Trades
2880
results found
FUND
DATE
ACTION
TICKER
COMPANY
SHARES
% of ETF
ARKG 29 Dec 2021 Buy SGFY SIGNIFY HEALTH INC 105,770 0.0279
ARKG 29 Dec 2021 Buy PSNL PERSONALIS INC 33,753 0.0088
ARKG 29 Dec 2021 Buy MASS 908 DEVICES INC 56,909 0.0269
ARKG 29 Dec 2021 Buy CRSP CRISPR THERAPEUTICS AG 14,400 0.0215
ARKG 29 Dec 2021 Buy BLI BERKELEY LIGHTS INC 50,528 0.0172
ARKG 29 Dec 2021 Buy BEAM BEAM THERAPEUTICS INC 5,855 0.0089
ARKG 28 Dec 2021 Sell TXG 10X GENOMICS INC 35,371 0.0965
ARKG 28 Dec 2021 Buy TDOC TELADOC HEALTH INC 33,000 0.0572
ARKG 28 Dec 2021 Buy PSNL PERSONALIS INC 78,949 0.0202
ARKG 28 Dec 2021 Buy NVTA INVITAE CORP 134,000 0.0383
ARKG 28 Dec 2021 Buy MASS 908 DEVICES INC 16,000 0.0075
ARKG 27 Dec 2021 Sell VRTX VERTEX PHARMACEUTICALS INC 41,298 0.1673
ARKG 27 Dec 2021 Sell ALLO ALLOGENE THERAPEUTICS INC 3,070 0.0009
ARKG 23 Dec 2021 Buy NRIX NURIX THERAPEUTICS INC 200 0.0001
ARKG 23 Dec 2021 Sell IONS IONIS PHARMACEUTICALS INC 35,468 0.0210
ARKG 22 Dec 2021 Buy NRIX NURIX THERAPEUTICS INC 28,900 0.0151
ARKG 22 Dec 2021 Sell IONS IONIS PHARMACEUTICALS INC 530 0.0003
ARKG 22 Dec 2021 Sell CDXS CODEXIS INC 55,872 0.0314
ARKG 21 Dec 2021 Sell IONS IONIS PHARMACEUTICALS INC 152,043 0.0924
ARKG 21 Dec 2021 Sell CDXS CODEXIS INC 184,851 0.1031
ARKG 20 Dec 2021 Sell VRTX VERTEX PHARMACEUTICALS INC 23,830 0.0939
ARKG 20 Dec 2021 Buy NRIX NURIX THERAPEUTICS INC 16,628 0.0085
ARKG 20 Dec 2021 Sell IONS IONIS PHARMACEUTICALS INC 61,200 0.0364
ARKG 20 Dec 2021 Sell CDXS CODEXIS INC 34,160 0.0183
ARKG 17 Dec 2021 Buy QSI QUANTUM-SI INC 26,126 0.0030
ARKG 17 Dec 2021 Buy PSNL PERSONALIS INC 4,900 0.0012
ARKG 17 Dec 2021 Buy MASS 908 DEVICES INC 1,499 0.0007
ARKG 16 Dec 2021 Buy QSI QUANTUM-SI INC 59,758 0.0066
ARKG 16 Dec 2021 Buy PSNL PERSONALIS INC 89,038 0.0220
ARKG 15 Dec 2021 Buy VCYT VERACYTE INC 10,400 0.0078
ARKG 15 Dec 2021 Buy QSI QUANTUM-SI INC 42,596 0.0047
ARKG 15 Dec 2021 Buy PSNL PERSONALIS INC 38,158 0.0093
ARKG 15 Dec 2021 Buy NTLA INTELLIA THERAPEUTICS INC 5,058 0.0107
ARKG 15 Dec 2021 Buy MASS 908 DEVICES INC 1,900 0.0008
ARKG 15 Dec 2021 Buy FATE FATE THERAPEUTICS INC 71,797 0.0678
ARKG 15 Dec 2021 Buy BEAM BEAM THERAPEUTICS INC 15,000 0.0214
ARKG 15 Dec 2021 Sell ALLO ALLOGENE THERAPEUTICS INC 54,518 0.0149
ARKG 15 Dec 2021 Buy ACCD ACCOLADE INC 50,489 0.0221
ARKG 14 Dec 2021 Buy VCYT VERACYTE INC 45,700 0.0340
ARKG 14 Dec 2021 Buy SLGC SOMALOGIC INC 187,013 0.0413
ARKG 14 Dec 2021 Buy SDGR SCHRODINGER INC/UNITED STATES 12,216 0.0083
ARKG 14 Dec 2021 Sell REGN REGENERON PHARMACEUTICALS INC 4,092 0.0510
ARKG 14 Dec 2021 Buy QSI QUANTUM-SI INC 51,318 0.0057
ARKG 14 Dec 2021 Buy PSNL PERSONALIS INC 100,496 0.0251
ARKG 14 Dec 2021 Sell PFE PFIZER INC 80,672 0.0837
ARKG 14 Dec 2021 Buy NTLA INTELLIA THERAPEUTICS INC 20,655 0.0441
ARKG 14 Dec 2021 Buy MASS 908 DEVICES INC 20,047 0.0091
ARKG 14 Dec 2021 Buy FATE FATE THERAPEUTICS INC 196,581 0.1821
ARKG 14 Dec 2021 Buy BLI BERKELEY LIGHTS INC 44,000 0.0148
ARKG 14 Dec 2021 Sell ALLO ALLOGENE THERAPEUTICS INC 1,581,099 0.4264
ARKG 14 Dec 2021 Buy ACCD ACCOLADE INC 116,240 0.0518
ARKG 13 Dec 2021 Buy SLGC SOMALOGIC INC 104,000 0.0238
ARKG 13 Dec 2021 Buy SDGR SCHRODINGER INC/UNITED STATES 132,257 0.0908
ARKG 13 Dec 2021 Sell REGN REGENERON PHARMACEUTICALS INC 12,000 0.1486
ARKG 13 Dec 2021 Buy QSI QUANTUM-SI INC 69,924 0.0080
ARKG 13 Dec 2021 Buy PSNL PERSONALIS INC 16,880 0.0042
ARKG 13 Dec 2021 Sell PFE PFIZER INC 155,578 0.1630
ARKG 13 Dec 2021 Buy ONEM 1LIFE HEALTHCARE INC 307,492 0.0992
ARKG 13 Dec 2021 Buy NVTA INVITAE CORP 22,000 0.0066
ARKG 13 Dec 2021 Buy MASS 908 DEVICES INC 24,600 0.0113
ARKG 13 Dec 2021 Buy CRSP CRISPR THERAPEUTICS AG 2,200 0.0030
ARKG 13 Dec 2021 Buy ACCD ACCOLADE INC 66,129 0.0295
ARKG 10 Dec 2021 Sell REGN REGENERON PHARMACEUTICALS INC 9,477 0.1178
ARKG 10 Dec 2021 Buy QSI QUANTUM-SI INC 82,963 0.0096
ARKG 10 Dec 2021 Buy NVTA INVITAE CORP 96,903 0.0295
ARKG 10 Dec 2021 Buy MASS 908 DEVICES INC 17,400 0.0082
ARKG 9 Dec 2021 Buy SLGC SOMALOGIC INC 33,736 0.0074
ARKG 9 Dec 2021 Buy QSI QUANTUM-SI INC 39,948 0.0045
ARKG 9 Dec 2021 Buy PATH UIPATH INC 245,247 0.2044
ARKG 9 Dec 2021 Buy NVTA INVITAE CORP 3,000 0.0009
ARKG 9 Dec 2021 Buy NTLA INTELLIA THERAPEUTICS INC 8,315 0.0168
ARKG 7 Dec 2021 Sell TAK TAKEDA PHARMACEUTICAL CO LTD 846,189 0.2311
ARKG 7 Dec 2021 Buy SGFY SIGNIFY HEALTH INC 160,234 0.0474
ARKG 6 Dec 2021 Buy TDOC TELADOC HEALTH INC 54,879 0.1000
ARKG 6 Dec 2021 Sell TAK TAKEDA PHARMACEUTICAL CO LTD 568,468 0.1500
ARKG 6 Dec 2021 Buy SLGC SOMALOGIC INC 231,353 0.0500
ARKG 6 Dec 2021 Buy QSI QUANTUM-SI INC 247,642 0.0300
ARKG 6 Dec 2021 Buy PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC 126,220 0.0500
ARKG 6 Dec 2021 Buy NTLA INTELLIA THERAPEUTICS INC 17,933 0.0300
ARKG 6 Dec 2021 Buy MASS 908 DEVICES INC 3,665 0.0000
ARKG 6 Dec 2021 Sell IOVA IOVANCE BIOTHERAPEUTICS INC 80,984 0.0300
ARKG 6 Dec 2021 Buy CRSP CRISPR THERAPEUTICS AG 28,000 0.0400
ARKG 6 Dec 2021 Sell BFLY BUTTERFLY NETWORK INC 422,692 0.0500
ARKG 6 Dec 2021 Buy BEAM BEAM THERAPEUTICS INC 25,920 0.0300
ARKG 3 Dec 2021 Buy SLGC SOMALOGIC INC 118,975 0.0300
ARKG 3 Dec 2021 Buy QSI QUANTUM-SI INC 74,968 0.0100
ARKG 3 Dec 2021 Buy MASS 908 DEVICES INC 39,800 0.0200
ARKG 3 Dec 2021 Sell IOVA IOVANCE BIOTHERAPEUTICS INC 25,500 0.0100
ARKG 3 Dec 2021 Buy DNA GINKGO BIOWORKS HOLDINGS INC 894,856 0.1500
ARKG 3 Dec 2021 Sell BFLY BUTTERFLY NETWORK INC 259,500 0.0300
ARKG 2 Dec 2021 Sell TAK TAKEDA PHARMACEUTICAL CO LTD 455,487 0.1153
ARKG 2 Dec 2021 Buy SLGC SOMALOGIC INC 52,635 0.0115
ARKG 2 Dec 2021 Buy MASS 908 DEVICES INC 107,633 0.0495
ARKG 2 Dec 2021 Sell IOVA IOVANCE BIOTHERAPEUTICS INC 104,800 0.0350
ARKG 2 Dec 2021 Sell INCY INCYTE CORP 26,601 0.0328
ARKG 2 Dec 2021 Buy DNA GINKGO BIOWORKS HOLDINGS INC 782,292 0.1510
ARKG 2 Dec 2021 Sell CSTL CASTLE BIOSCIENCES INC 280,518 0.2170
ARKG 2 Dec 2021 Sell CDXS CODEXIS INC 79,354 0.0520
ARKG 2 Dec 2021 Sell BFLY BUTTERFLY NETWORK INC 61,756 0.0082
ARKG 30 Nov 2021 Buy VCYT VERACYTE INC 1,187 0.0000
Latest Blogs
ARK by Cathie Wood is still suffering a year after its apex.

Cathie Wood's flagship exchange-traded fund hit an all-time high in February of this year. Her preferred disruptive-tech chasing strategy may still be in for a lot of suffering after a year and a 53 percent fall.

After a dramatic decline last month, the ARK Innovation ETF (ticker: ARKK) has steadied off - it's practically flat in February – but the headwinds surrounding its speculative growth picks are just becoming more vital. Many businesses that thrived during the pandemic are being hammered by the economic reopening, not only because yields are rising as investors prepare for the US Federal Reserve to raise interest rates, which is terrible news for unprofitable businesses, but also because the economic reopening is hammering many of the businesses that thrived during the pandemic.

Roku, Teladoc, and Zoom, all winners in the work-from-home era, have had their stock prices plummet by as much as 74% in the past year.

Short bets against ARK, according to IHS Markit data, hit a fresh high of 11.4 percent of outstanding shares this week. The Tuttle Capital Short Innovation ETF (SARK), which beats the ARK, now has assets worth more than $US300 million ($416 million).

"Those equities are supported by speculation, and speculation pays less well when the Fed raises rates," said Brent Schutte, chief investment strategist at Northwestern Mutual Wealth Management Co. "Much of what's happening in the market reminds me of what happened in the late 1990s when market segments were bid up to levels based on future assumptions."

Because its price chart resembles that of the Nasdaq index of technology businesses from more than two decades ago, analogies to that period and the dot-com implosion that followed are becoming more common in discussions of ARK.

"Today marks the 253rd trading day from ARK's all-time high," Jessica Rabe, co-founder of DataTrek Research, wrote in a Tuesday note, "while the Nasdaq was down 60% from its dot-com bubble top on the same day in 2001."

"If 2000/2001 analog holds, we should see ARK continuing to fall over the following three weeks. The Nasdaq dropped 18.7% in the next 16 trading days "recent."

Net flows are positive.

The better news for investors and Ms. Wood is that there may be some immediate respite. The Nasdaq rose 41% in six weeks in 2001 before falling.

The ARK Investment Management did not respond to a request for comment.

Most of ARK's $US15 billion asset loss has been attributed to bad performance, a plus for the company. Since the fund achieved an intraday high of $US159.70 a year ago this week, investors have withdrawn only around $US465 million, and ARK's net flows this year are positive despite a more than 20% drop.

This exceptional loyalty prevents a worsening situation and allows Wood's approach to recovering. The star fund manager has consistently emphasized that her funds have a five-year investment horizon and that she believes in many good options.

Mr. Schutte, on the other hand, says the drop is understandable because several of the company's biggest bets, such as Teladoc and Zoom, are becoming less significant as COVID-19 approaches.

"During the pandemic, there were a lot of questions about what would happen to society and how we'd go about our lives," he added.

"You drew in new investors who wanted to know "what are the upcoming themes I should invest in?" I believe you got a washout of it as well."

On Friday, Cathie Wood sold $148.9 million worth of Palantir stock, halving her exposure.

Ark Investment Management, run by Cathie Wood, sold more Palantir Technologies Inc PLTR -6.39 percent shares on Friday, cutting its stake in the Peter Thiel-backed company.

According to Friday's closing price, the famous investment management firm sold 13.5 million shares of the big data company, valued at $148.9 million.

Palantir's stock fell 6.4 percent to $11.02 per share on Friday. The stock has lost 16% of its value in the last week.

Before Friday's trade, Ark Invest held 25.53 million shares in Palantir, suggesting that the famous stock picker had trimmed over 52 percent of its total keeping a day later.

After the business disclosed lower-than-expected fourth-quarter earnings before the market opened on Thursday, Ark Invest, located in St. Petersburg, California, dumped shares in Palantir for the second time.

The software firm, well-known for its work with government organizations, posted earnings of 2 cents per share, falling short of the analyst consensus of 4 cents. The company recorded quarterly revenues of $432.87 million, higher than the $417.69 million predicted by analysts.

Palantir's stock had been sold for 4.77 million shares by the investment firm the day before.

All six of Ark Invest's active exchange-traded funds own Palantir stock, including the flagship Ark Innovation ETF ARKK -4.88 percent.

Before the recent sell-off, Ark Invest had been stockpiling Palantir shares for months.

Cathie Wood appeared on television to defend her ARK funds' dismal performance. It didn't go quite as planned.

The Ark Innovation ETF (ARKK), Cathie Wood's flagship fund, is down 30% year to date and more volatile than almost any other fund on the market. On CNBC's Halftime Report, Wood jumped at the chance to defend the fund and its deflated price, which is currently $68.80, down from $155 a year ago.

"We've seen a significant decline," Wood said, adding, "We feel innovation is at bargain basement zone." Even though her ETF was underperforming, she emphasized that her companies were still "very inexpensive" and that the current fund loss was temporary. When the call's 40 free minutes were finished, Zoom gave her an extra 10 minutes to complete the interview.

Having Zoom check to see whether she was "running out of time?" Wood, who has been aggressively buying up shares in Zoom and other IT firms that have fallen from their pandemic highs, was unhappy. Zoom, like Wood's other significant tech holdings, Teladoc Health, Roku, and Roblox, is down 20% to 40% year to date as investors worry about rising interest and inflation rates.

However, a significant chunk of the interview was devoted to a personal assault on Cathie Wood, who was named the most excellent stock picker in 2020 by Bloomberg's then-Editor-in-Chief Matthew Winkler after correctly forecasting that Tesla will one day be valued at more than $1 trillion.

Wood bluntly ignored Tuttle Capital Management's Short Innovation ETF (SARK), which tracks the inverse performance of ARKK using swaps contracts for the sole purpose of betting against Cathie Wood's selections. "They're not conducting any research." She explained, "All they're doing is shorting innovation."

Of course, SARK is betting against Cathie Woods, not on innovation. "Well, we stand for invention," Wood responded. The SARK ETF has gained 55 percent since its debut, whereas the ARKK ETF has declined by 42 percent.

Tuttle Capital Management CEO Matthew Tuttle chimed in on the SARK ETF, calling it a "tool" for investors. According to SARK, "to convey a negative view of the market, innovative enterprises, the current rising rate environment, or a [specific] portfolio manager if they wish." "It's un-American not to have options in the marketplace," Tuttle told Insider on Thursday.

In any event, Wood is making progress. Her main concern currently is bearish calls on her ETF. "Our major concern is that our investors convert temporary losses into long-term losses," Wood continued.